GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Shiller PE Ratio

Incyte (WBO:INCY) Shiller PE Ratio : 57.67 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Incyte Shiller PE Ratio?

As of today (2024-05-27), Incyte's current share price is €70.36. Incyte's E10 for the quarter that ended in Mar. 2024 was €1.22. Incyte's Shiller PE Ratio for today is 57.67.

The historical rank and industry rank for Incyte's Shiller PE Ratio or its related term are showing as below:

WBO:INCY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 52.2   Med: 135.54   Max: 261.53
Current: 57.89

During the past years, Incyte's highest Shiller PE Ratio was 261.53. The lowest was 52.20. And the median was 135.54.

WBO:INCY's Shiller PE Ratio is ranked worse than
69.93% of 153 companies
in the Biotechnology industry
Industry Median: 33.74 vs WBO:INCY: 57.89

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Incyte's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.690. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €1.22 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Shiller PE Ratio Historical Data

The historical data trend for Incyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Shiller PE Ratio Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 245.29 155.17 72.06

Incyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.93 95.69 76.96 72.06 57.55

Competitive Comparison of Incyte's Shiller PE Ratio

For the Biotechnology subindustry, Incyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Shiller PE Ratio falls into.



Incyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incyte's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=70.36/1.22
=57.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Incyte's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.69/131.7762*131.7762
=0.690

Current CPI (Mar. 2024) = 131.7762.

Incyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.162 100.560 -0.212
201409 0.256 100.428 0.336
201412 -0.178 99.070 -0.237
201503 -0.102 99.621 -0.135
201506 0.045 100.684 0.059
201509 -0.196 100.392 -0.257
201512 0.266 99.792 0.351
201603 0.108 100.470 0.142
201606 0.160 101.688 0.207
201609 0.169 101.861 0.219
201612 0.047 101.863 0.061
201703 -0.898 102.862 -1.150
201706 -0.053 103.349 -0.068
201709 0.143 104.136 0.181
201712 -0.600 104.011 -0.760
201803 -0.154 105.290 -0.193
201806 0.205 106.317 0.254
201809 0.120 106.507 0.148
201812 0.281 105.998 0.349
201903 0.416 107.251 0.511
201906 0.425 108.070 0.518
201909 0.536 108.329 0.652
201912 0.459 108.420 0.558
202003 -3.014 108.902 -3.647
202006 1.172 108.767 1.420
202009 -0.059 109.815 -0.071
202012 0.559 109.897 0.670
202103 0.202 111.754 0.238
202106 0.556 114.631 0.639
202109 0.697 115.734 0.794
202112 2.248 117.630 2.518
202203 0.154 121.301 0.167
202206 0.681 125.017 0.718
202209 0.505 125.227 0.531
202212 0.123 125.222 0.129
202303 0.093 127.348 0.096
202306 0.831 128.729 0.851
202309 0.712 129.860 0.723
202312 0.816 129.419 0.831
202403 0.690 131.776 0.690

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (WBO:INCY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Incyte Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Incyte's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (WBO:INCY) Business Description

Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.